Lund, Sweden, 18:30 CET, 18 July 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that Michael Diefenbeck MD PhD, BONESUPPORT’s Chief Medical Officer, has been appointed to assume a broader role as Head of R&D, Medical and Clinical ... read more

  Solid cash position of €13.5 million at June 30, 2018 Key highlights of H1 2018: primary objective met in the first results of TARGET PHASE II study and with the strategic partnership with the University of North Texas Health Science Center Key perspectives by the end of 20... read more

Funds to be used to continue the clinical development of sevuparin for sickle cell disease STOCKHOLM, SWEDEN – 13 July 2018: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell disease (SCD), announces that it has ... read more

GAITHERSBURG, Md., July 12, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has entered into agreements with substantially all of the remaining investors in its Series B Financing to ... read more

Oslo, Norway, 12 July 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors, and SOTIO, a biotechnology company owned by the PPF Group, announce that the first patient has been dosed with ONCOS-102 i... read more